Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBITDA (2016 - 2025)

Historic EBITDA for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$73.1 million.

  • Ascendis Pharma A's EBITDA rose 3275.88% to -$73.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $409.1 billion, marking a year-over-year increase of 10030446.58%. This contributed to the annual value of -$301.7 million for FY2024, which is 3844.23% up from last year.
  • Per Ascendis Pharma A's latest filing, its EBITDA stood at -$73.1 million for Q3 2025, which was up 3275.88% from -$45.6 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's EBITDA ranged from a high of $409.3 billion in Q4 2024 and a low of -$176.0 million during Q3 2023
  • For the 5-year period, Ascendis Pharma A's EBITDA averaged around $21.4 billion, with its median value being -$117.8 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 46705.63% in 2021, then soared by 103912092.86% in 2024.
  • Over the past 5 years, Ascendis Pharma A's EBITDA (Quarter) stood at -$128.8 million in 2021, then decreased by 16.76% to -$150.4 million in 2022, then skyrocketed by 73.8% to -$39.4 million in 2023, then surged by 1039120.93% to $409.3 billion in 2024, then plummeted by 100.02% to -$73.1 million in 2025.
  • Its EBITDA stands at -$73.1 million for Q3 2025, versus -$45.6 million for Q2 2025 and -$99.6 million for Q1 2025.